Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00010127 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
A Phase 1 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT00010127 is a Phase 1 study that was terminated before completion, run by Duke University. The registered enrollment target is 3 participants.
The verdict
NCT00010127, a Phase 1 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill prostate tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic prostate cancer.
Interventions
- BIOLOGICAL therapeutic autologous dendritic cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2000-11 |
| Est. Completion | 2003-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00010127
The ClinicalTrials.gov registry entry for NCT00010127 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which therapeutic autologous dendritic cells is the first listed.
NCT00010127 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00010127 about?
NCT00010127 is a clinical study titled "Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer". RATIONALE: Vaccines made from a person's cancer cells may make the body build an immune response to kill prostate tumor cells. PURPOSE: Phase I trial to study the effectiveness of vaccine therapy in treating patients who have metastatic prostate cancer.
What is the current status of trial NCT00010127?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2000-11. Estimated completion is 2003-03.
What interventions are being tested in trial NCT00010127?
The interventions under investigation include: therapeutic autologous dendritic cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT00010127?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.